PMID- 11248334
OWN - NLM
STAT- MEDLINE
DCOM- 20010426
LR  - 20190826
IS  - 0145-2126 (Print)
IS  - 0145-2126 (Linking)
VI  - 25
IP  - 4
DP  - 2001 Apr
TI  - Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine 
      A for modulation of donor CD3 cells activity with monitoring of minimal residual 
      disease and cellular chimerism in a patient with first hematologic relapse of 
      chronic myelogenous leukemia after allogeneic bone marrow transplantation.
PG  - 353-7
AB  - A 15-year-old girl with Ph-positive chronic myelogenous leukemia in first chronic 
      phase received bone marrow from her human leukocyte antigen matched brother. 
      Twenty three months after bone marrow transplantation hematological relapse 
      occured which was treated with two infusions of donor lymphocytes (DLI) 
      (0.5x10(8) CD3/kg b.w./infusion). To enforce the graft-versus-leukemia effect 
      (GvL), the first DLI was followed by administration of interferon-alpha 
      (INF-alpha) 6x10(6) U/day for 30 days, whereas, after the second infusion 
      INF-alpha was given at the same dose until hematological remission was achieved 
      (80 doses). Minimal residual disease (MRD) was detected by conventional 
      cytogenetics (Ph chromosome), fluorescence in situ hybridization (FISH) 
      cytogenetics (BCR/ABL translocation) and reverse transcriptase-polymerase chain 
      reaction (RT-PCR) Ecotropic virus integration site-1 (EVI-1 gene expression), 
      whereas cellular chimerism was monitored by assessment of microsatellite markers 
      PCR and Y-chromosomal DNA content FISH. When hematological remission was achieved 
      the pancytopenia was observed and the cytogenetic and molecular investigations 
      revealed only partial remission and mixed chimerism, however, with predominance 
      of donor origin hematopoiesis. To diminish the myelosupressive effect of donor 
      CD3 cells without switching-off the GvL effect, a low dose of cyclosporine A was 
      given. Further observation revealed significant improvement of hematopoiesis with 
      parallel gradual decline of MRD and increase of donor hematopoiesis up to 
      complete chimerism. Graft-versus-host disease was not observed at any stage of 
      the treatment.
FAU - Leda, M
AU  - Leda M
AD  - BMT Unit CIC 641, Institute of Pediatrics, University of Medical Sciences, ul. 
      Szpitalna 27/33, 60-572, Poznan, Poland.
FAU - Ladon, D
AU  - Ladon D
FAU - Pieczonka, A
AU  - Pieczonka A
FAU - Boruczkowski, D
AU  - Boruczkowski D
FAU - Jolkowska, J
AU  - Jolkowska J
FAU - Witt, M
AU  - Witt M
FAU - Wachowiak, J
AU  - Wachowiak J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (CD3 Complex)
RN  - 0 (Interferon-alpha)
RN  - 83HN0GTJ6D (Cyclosporine)
SB  - IM
MH  - Adolescent
MH  - Bone Marrow Transplantation/methods
MH  - CD3 Complex/blood/drug effects
MH  - Cyclosporine/administration & dosage
MH  - Female
MH  - Graft vs Leukemia Effect/drug effects
MH  - Humans
MH  - Interferon-alpha/administration & dosage
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/*therapy
MH  - Lymphocyte Transfusion/*methods
MH  - Neoplasm, Residual
MH  - Recurrence
MH  - Transplantation Chimera
MH  - Transplantation, Homologous/methods
EDAT- 2001/03/15 10:00
MHDA- 2001/05/01 10:01
CRDT- 2001/03/15 10:00
PHST- 2001/03/15 10:00 [pubmed]
PHST- 2001/05/01 10:01 [medline]
PHST- 2001/03/15 10:00 [entrez]
AID - S0145-2126(00)00143-0 [pii]
AID - 10.1016/s0145-2126(00)00143-0 [doi]
PST - ppublish
SO  - Leuk Res. 2001 Apr;25(4):353-7. doi: 10.1016/s0145-2126(00)00143-0.